ABSTRACT
The pandemic caused by the coronavirus of severe acute respiratory syndrome 2 (SARS-CoV-2), the etiological agent of the 2019 coronavirus disease (COVID-19), represents a threat of great magnitude not faced in this century. As a result, each government has proposed emergency public health measures that are critical to delay the transmission and spread of the virus and mitigate its impacts. In Brazil, the outbreak triggered many cases of people infected with COVID-19. Considering there are no drugs or vaccines proven to be effective to treat the disease, analyzing the data of infection cases and their mathematical interpretation are essential for supporting and guiding governmental measures to suppress and mitigate the impact of COVID-19. This means that estimates with mathematical models to assess the development potential of sustained human-human transmission are needed. Since the disease has its own biological characteristics, the models need to be adapted to the variability of the regions’ characteristics and the decision-making by both the government and the population, in order to be able to deal with real situations. Thus, in the present paper, we analyzed the official data of COVID-19 in Brazil and used the Johnson-Mehl-Avrami-Kolmogorov (JMAK) equation to predict the evolution of the disease. The model indicates that a nucleation rate is of fourth order, which indicates that Brazilians are crowding with no respect to measures of social distance and disease prevention. In our opinion, the political authorities were unable to control the spread of the disease in Brazil, given that social mobility was interrupted by the federal and state governments.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This research was carried out with official data provided by the Ministry of Health of Brazil (https://covid.saude.gov.br/). There was no intention with patients and people infected with covid-19. Since the data we used was anonymous and available for the general public, according to Ordinance 466/2012 from the National Health Council, the research did not need approval from the Human Research Ethics Committee.
Clinical Protocols
https://bvsms.saude.gov.br/bvs/saudelegis/cns/2013/res0466_12_12_2012.html
Funding Statement
Financial support: none.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Does not apply in this case
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interests: nothing to declare – Financial support: none.
Data Availability
We searched for epidemiologic bulletins in all Brazilian local government websites and the Federal District that are summarized in .https://covid.saude.gov.br/